Arcosa, Inc. (ACA) Stock Price & How to Invest

Arcosa was spun out of Trinity Industries in late 2018 and has spent the years since reshaping itself from a diversified industrial into an infrastructure materials company. It now reports two segments. Construction Products sells aggregates, specialty materials such as recycled asphalt and lightweight aggregate, and construction site support, and generated roughly $357.0 million of revenue in the second quarter of 2026. Engineered Structures builds utility poles and steel structures, wind towers, telecom and traffic structures, and storage tanks, and generated roughly $301.7 million. The portfolio pruning has been aggressive: the steel components business went in 2025, and the barge business was sold on April 1, 2026 for approximately $450 million, producing a pre-tax gain of roughly $359.7 million and moving barge results into discontinued operations. On the other side of the ledger, the roughly $1.2 billion Stavola acquisition in late 2024 added asphalt and aggregates positions in the New York and New Jersey metro market.

The defining fact for anyone looking at ACA today is the merger. On June 22, 2026, CRH announced an agreement to acquire all of Arcosa for $150.00 per share in cash, an enterprise value of roughly $8.5 billion, or about 11.5 times 2026 estimated adjusted EBITDA including roughly $175 million of expected run-rate cost synergies by year three. Arcosa filed its definitive proxy on August 3, 2026, set a special stockholder meeting for September 4, 2026, and expects to close in the first quarter of 2027 subject to that vote and regulatory clearance. Management has suspended full-year guidance and stopped holding quarterly earnings calls. With the stock near $145 against a $150 offer, the residual price movement mostly reflects the market's view of deal completion odds and timing, not aggregate volumes in Texas.

The largest risk is deal failure. If the CRH transaction does not close, whether through the stockholder vote, antitrust review of overlapping aggregates positions, or a financing or regulatory delay past the expected first-quarter 2027 close, the share price would no longer be supported by the $150 offer and could revert toward where it traded before June 2026, well under the current level. Plaintiffs' firms including Monteverde & Associates have publicized investigations of the merger process; as of August 2026 those are solicitations rather than a filed securities-fraud complaint, but merger-related disclosure suits are common and can add noise. Underlying business risks remain: heavy exposure to Texas and Southwest construction weather and cycles, wind tower demand that depends on federal incentives and utility procurement, and leverage carried since the roughly $1.2 billion Stavola acquisition. Trailing earnings are also distorted by the roughly $359.7 million pre-tax barge gain, so headline trailing EPS and the trailing P/E overstate ongoing profitability.

3 analysts publish price targets on ACA, averaging $146.67 against a $144.84 price as of August 2026, or +1.3%. The published targets run from $140.00 to $150.00, a narrow spread, and the ratings split 1 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ACA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Arcosa, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The CRH merger sets the price. A $150 per share all-cash agreement caps most of the upside and defines the risk. The most optimistic published target, $150.00, assumes this works close to its best case.

The case against. The largest risk is deal failure. The most pessimistic target, $140.00, is roughly what ACA is worth if this bites instead.

Read the full bull and bear case on ACA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Arcosa, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.9B
• Q2 2026 revenue (continuing ops): ~$658.7M, up ~2% year over year
• Q2 2026 adjusted EBITDA: ~$145.9M, ~22.1% margin
• Market cap / enterprise value: ~$7.1B / ~$8.2B
• EV / EBITDA: ~15x trailing; the CRH deal is ~11.5x 2026E adjusted EBITDA including synergies
• Merger terms: $150.00 per share cash, ~$8.5B, vote set for September 4, 2026, close expected Q1 2027

Trailing net income of roughly $491 million and trailing EPS near $9.98 are inflated by the roughly $359.7 million pre-tax gain on the April 2026 barge sale, which makes the trailing P/E near 32x misleading as an operating multiple. Fiscal 2025 is the cleaner reference point: revenue of roughly $2.88 billion, operating income of roughly $341.9 million and EPS of about $4.24. The dividend is nominal at $0.20 a share, a yield near 0.14 percent, and full-year 2026 guidance has been withdrawn because of the merger.

Other names that sit close to ACA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ACA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ACA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ACA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Arcosa is a real, profitable aggregates and structures business whose share price is now anchored to a pending $150 all-cash takeout rather than to its own quarterly results.

Whether ACA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ACA a buy or a sell?, and where the stock could go from here in the ACA stock forecast.

For income investors, whether ACA pays a dividend and how the payout looks is covered in does ACA pay a dividend? And to weigh ACA against a peer, read the full side-by-side comparisons: ACA vs VMC and ACA vs MLM.